By clicking submit I agree to be contacted by Frank Leo via call, email, and text. To opt-out, you can reply 'stop' at any time or click the unsubscribe link in the emails. Message and data rates may apply.

    Britain has allowed a conditional authorization to use Merck’s coronavirus antiviral pill in the country. The pill has been shown to successfully treat COVID-19  and the U.K. is the first country to approve the treatment. However, it is still not clear when the pill will be available to the public.

    The pill is meant for adults 18 and older who have tested positive for COVID-19 and have one risk factor for developing severe disease. The pill contains a drug called molnupiravir and is intended to be taken twice daily for five days. As an antiviral pill, it helps reduce symptoms and speeds recovery which will be very beneficial to the healthcare system

    The drug is also pending review in the U.S., Canada, Europe, and other nations. The U.S. Food and Drug Administration announced last month a panel of independent experts will scrutinize the safety and effectiveness in late November. Supplies will be limited as the company said they can only produce 10 million treatment courses by the end of the year.

    For more information about the source click HERE